Journals / Çukurova Üniversitesi Tıp Fakültesi Dergisi / 1999 / Cilt: 24 - Sayı: 3

Familial hypertrophic cardiomyopathy: A case report

Ailevi hipertrofik kardiyomyopati: Olgu sunumu

Pages
110–115
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, familial hypertrophic cardiomyopathy cases were presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypertrophic cardiomyopathy (HCM) is a genetic disease inherited as otosomal dominant, with frequency of %0,01 -0,1.There are several studies which describes HCM in different races in whom, prognosis and the type of ventricular involvement have shown some alterations.
📊
Key Findings & Data:Apical involvement is more frequent in the Japanese people where as the severity of hypertrophy and frequency of sudden death in Greece is less when compared with North Europe and North America In the half of the cases, familial inheritance is seen, however the disease is sporadically present for the rest.
💡
Conclusion & Impact:In this review, familial hypertrophic cardiomyopathy cases were presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disease inherited as otosomal dominant, with frequency of %0,01 -0,1.There are several studies which describes HCM in different races in whom, prognosis and the type of ventricular involvement have shown some alterations. Apical involvement is more frequent in the Japanese people where as the severity of hypertrophy and frequency of sudden death in Greece is less when compared with North Europe and North America In the half of the cases, familial inheritance is seen, however the disease is sporadically present for the rest. The severity and the distribution of the hypertrophy, the starting age, and the severity of clinical manifestations are variable. Major pathology consists of the inflammation and hypertrophy of cardiac muscles and sarkomer irregularity. In this review, familial hypertrophic cardiomyopathy cases were presented.

Özet

Hipertrofik kardiyomiyopati (HK) otozomal dominant geçiş gösteren genetik bir hastalıktır ve toplumda %0.01-0.1 oranında görülmektedir. Bütün ırklarda tanımlanmış olmakla beraber farklı ırk gruplarında HK' nin prognozu ve ventrikülün tutulum biçimi değişkenlik gösterebilir. Japonlarda apikal tutulum daha sık görülürken, Yunanlılarda hipertrofinin şiddeti ve ani ölüm sıklığı Kuzey Avrupa ve Kuzey Amerikalılara göre daha azdır. Olguların yarısında ailevi geçiş olduğu, geri kalanlarda ise sporadik olarak görüldüğü saptanmıştır. Hipertrofinin derecesi, dağılımı, hastalığın başlangıç yaşı, klinik belirtilerinin tipi ve ciddiyeti de değişkendir. Belirgin kardiyak patolojiyi miyozit hipertrofisi ve sarkomer düzensizliği oluşturmaktadır. Bu yazıda ailevi geçiş gösteren hipertrofik kardiyomiyopati olguları sunulmuştur.

🔖

Cite This Article

AKSOY, M. F., BOZKURT, A., ACARTÜRK, E., SÜLEYMANOVA, D., BİRAND, A. (2022). Familial hypertrophic cardiomyopathy: A case report. Çukurova Üniversitesi Tıp Fakültesi Dergisi, Cilt: 24 - Sayı: 3, 110–115. https://ajindex.com/articles/486209

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Agnarsson UT, Hardarson T, Hallgrimsson J, et al. The prevalance of hypertrophic cardiomyopathy in men: an echocardiographic population screning study with a rewiew of death records. J Intern Med 1992;232: 499-506
  2. Alfonso F, Nihoyannopoulos P, Stewart J, et al. Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:965-971
  3. Ando H, Ýmaizumi T, Urabe Y, et al. Apikal segmental dysfunction in hypertrophic cardiomyopathy: Subgroup with unique clinical features. J Am Coll Cardiol 1990; 16:1579-1588
  4. Braunwald E. Current therapy of hypertrophic cardiomyopathy. Eur Heart J 1997; 18:709-710
  5. Braunwald E. Heart disease. 5th Ed, Philadelphia: W.B. Saunders Company.1997:1414-1426
  6. Chikamori T, Counihan PJ, Doi YL, et al. Mechanism of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19;507
  7. Codd MB, Sugrue DD, Gerch BJ, et al. Epidemyology of idiopathic dilated hypertrophic cardiomyopathy: a population based study in Olmsted Country, Minnesota, 1975-1984. Circulation 1989; 80:564-569
  8. Doi YL, McKenna WJ, Gehrke J, et al. M mode echocardiography in hypertrophic cardiomyopathy: Diagnostic criteria and prediction of obstruction. Am J cardiol 1980; 45:6-14
  9. Geisterfer-Lawrence AA, Kass J, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta-cardiac myosin heavy chain gene missence mutation. Cell 1990; 62:999-1006
  10. Jarcho JA, McKenna W, Pare P, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromozome 14q1. N Engl J Med 1989; 321:1372-1378
  11. Louie EK, Maron BJ. Apical hypertrophic cardiomyopathy: Clinical and two dimensional echocardiyographic assesment. Ann Intern Med 1987; 106:663-670
  12. Marian AJ, Roberts R:Recent advences in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995; 92:1336-1347
  13. Maron BJ, Ýsner JM, Mc Kenna WJ. 26th Bethesda Conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: Hypertrophic cardiomyopathy, myocarditis and myopericardial diseases and mitral valv prolapsus. J Am Coll Cardiol 1994; 24:880 14. Maron BJ. Q waves in hypertrophic cardiomyopathy.J Am Coll Cardiol 1990; 16:375-376
  14. Maron, BJ. Hypertrophic cardiomyopathy. Curr Probl Cardiol; 1993:18:639
  15. McKenna WJ, Kleinebenne A, Nihoyanopoulos P, et al. Echocardiographic measurment of right ventricular wall thickness in hyp